Weakness of leukemic stem cells discovered

5-LO inhibitors eliminate cells in culture and mouse models

2014-08-04

(Press-News.org) FRANKFURT. Despite improved therapy, only one out of every two adult patients survive acute myeloid leukaemia (AML). The mean survival time for this disease, which predominantly occurs in the elderly, is less than a year for patients over 65 years. It is assumed that leukaemic stem cells, which cannot be completely eliminated during treatment, are the origin of relapse. However, as has been discovered by a team of Frankfurt-based researchers, these cells do have a weakness: In the current edition of the high impact journal "Cancer Research", they report that the enzyme 5-lipoxygenase (5-LO) plays a significant role in the survival of leukaemic AML stem cells.

5-LO is known for its role in inflammatory diseases like asthma. A team led by Dr. Marin Ruthardt from the Haematology Department of the Medical Clinic II and Dr. Jessica Roos, Prof. Diester Steinhilber and Prof. Thorsten Jürgen Maier from the Institute for Pharmaceutical Chemistry showed that the leukaemic stem cells in a subgroup of AML could be selectively and efficiently attacked by 5-LO inhibitors. This was demonstrable in cell culture models as well as in leukaemia mouse models.

"These results provide the basis for the potential implementation of 5-LO-inhibitors as stem cell therapeutic agents for a sustained AML cure, although this must be investigated further in preclinical and clinical studies in humans," explains Dr. Ruthardt. "In addition, there are plans for further molecular biological studies with the objective of understanding exactly how the 5-LO inhibitors act on the leukaemic cells." Prof. Maier continued.

INFORMATION: Publication: Roos et al.: 5-lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia, in Cancer Research Volume (2014), Published OnlineFirst July 31, 2014; doi:10.1158/0008-5472.CAN-13-3012

Information PD Dr. Martin Ruthardt, Haematology/Medical Clinic II, Tel. +49/ 69/6301-5338, email: ruthardt@em.uni-frankfurt.de or Prof. Dr. Thorsten Jürgen Maier, Institute for Pharmaceutical Chemistry, Riedberg Campus, Tel.: +49/69/7982-934, email: maier@pharmchem.uni-frankfurt.de.

The Goethe University is an institution with particularly strong research capabilities based in the European financial metropolis of Frankfurt. It celebrates its 100th year of existence in 2014. The university was founded in 1914 through private means from liberally-orientated citizens of Frankfurt and has devoted itself to fulfilling its motto "Science for the Society" in its research and teaching activity right up to the present day. Many of the founding donors were of Jewish origin. During the last 100 years, the pioneering services offered by the Goethe University have impacted the fields of social, societal and economic sciences, chemistry, quantum physics, neurological research and labour law. On January 1st, 2008, it achieved an exceptional degree of independence as it returned to its historical roots as a privately funded university. Today it is one of the ten universities that are most successful in obtaining external research funding and one of the three largest universities in Germany with centres of excellence in medicine, life sciences and humanities. Publisher: The president of the Goethe University Frankfurt am Main. Editorial department: Dr. Anne Hardy, Public Relations Officer for Scientific Communication. Abteilung Marketing und Kommunikation, Grüneburgplatz 1, 60629 Frankfurt am Main, Phone: (069) 798-12498.

ELSE PRESS RELEASES FROM THIS DATE:

Minuscule chips for NMR spectroscopy promise portability, parallelization

2014-08-04

Cambridge, Mass. – August 4, 2014 – A team of engineers at the Harvard School of Engineering and Applied Sciences (SEAS), Schlumberger-Doll Research Center in Cambridge, Mass., and the University of Texas, Austin, have created a truly portable device for nuclear magnetic resonance (NMR) spectroscopy. NMR spectroscopy is a technique that perturbs protons within a molecule to glean important clues about its structure. It can identify unknown substances, detect very slight variations in chemical composition, and measure how molecules interact, making it an essential tool ...

The evolution of migration

2014-08-04

Each year, millions of birds migrate thousands of miles between the locations where they breed and raise young, and the areas where they spend the winter. Each migration is a trip fraught with danger—many birds die before they reach their final destination. To scientists, long distance migration still holds many mysteries, one of which is: where did migration begin and how did it evolve? This question has long been a debated topic among scientists, but thanks to new research from Field Museum scientists, we may have an answer for one of the largest groups of migratory birds. ...

Flores bones show features of Down syndrome, not a new 'hobbit' human

2014-08-04

In October 2004, excavation of fragmentary skeletal remains from the island of Flores in Indonesia yielded what was called "the most important find in human evolution for 100 years." Its discoverers dubbed the find Homo floresiensis, a name suggesting a previously unknown species of human. Now detailed reanalysis by an international team of researchers including Robert B. Eckhardt, professor of developmental genetics and evolution at Penn State, Maciej Henneberg, professor of anatomy and pathology at the University of Adelaide, and Kenneth Hsü, a Chinese geologist and ...

Triple therapy revs up immune system against common brain tumor

2014-08-04

A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report by scientists at the Johns Hopkins Kimmel Cancer Center. Mice with implanted, mouse-derived glioblastoma cells lived an average of 67 days after the triple therapy, compared with mice that lasted 24 days when they received only the two immunotherapies. Half of the mice who received the triple therapy lived 100 days or more and were protected against further tumors when new cancer ...

African American professional women positive on medical research

2014-08-04

ROCHESTER, Minn. — If a research survey of African American professional women is any indication, attitudes may be changing towards participation in medical research. Mayo Clinic and The Links, Incorporated researchers teamed up to survey members of the international women's organization, and found that a majority of African American women surveyed are willing to or have taken part in medical research. The results appear in the Journal of Women's Health. "Our findings are highly encouraging," says Sharonne Hayes, M.D., Mayo Clinic cardiologist, co-author of the study, ...

Fires in California and Oregon

2014-08-04

The Little Deer fire in California began as a lightning strike on July 31, 2014. Currently it has burned 4,700 acres and is 43% contained however there has been increased humidity over the fire the last 24 hours with shifting wind conditions. The threat of thunder storms today (08/04) and tomorrow (08/05) may cause an increase in fire activity. The Beaver Complex is comprised of the Salt Creek Fire (20 miles northwest of Medford) and the Oregon Gulch Fire (15 miles east of Ashland), which are lightning-started fires that started on July 30-31, 2014. After it was first ...

Eiler and Bald Fires in California

2014-08-04

The Eiler wildfire which began on July 31, 2014, has almost consumed 26,000 acres. It is currently unknown as to the cause of this fire. The weather patterns currently around this fire do not bode well for a quick containment. Maximum temperatures are in the mid- to high 80's with 10-20% relative humidity. There is an unstable atmosphere at work along with thunderstorm chances which are increasingly today (08/04) through Wednesday (08/06). A Red Flag Warning in effect for dry lightning on Monday (08/04). The Bald Fire began with a lightning strike on July 30, 2014. ...

Smoke from Canadian wildfires over Baffin Bay

2014-08-04

Canadian wildfires have been raging this summer and some of the smoke from those fires already drifted downward into the U.S. over the Great Lakes (see the image feature from July 25 below). In this image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua satellite on August 02, 2014 the large swath of smoke from these fires has taken a northward track and settled over the Bay of Baffin which borders Greenland. To view the other Canadian fire images from July 2014: Smoke from Canadian Fires Hovers Over Great Lakes - July 25, 2014 Smoke ...

Wildfires consume parts of eastern Russia

2014-08-04

Wildfires in far eastern Russia dot the landscape and what isn't covered by the fires is covered by the smoke that rises from these wildfires. This image taken by the Terra satellite shows the entire area covered with a blanket of heavy smoke coming off of dozens of wildfires that have broken out in the remote areas of Russia. Usually these fires are caused by lightning strikes that then consume the dry vegetation. With nothing to stop the spread, these fires take off and cover the landscape, especially during this time of year.INFORMATION: NASA's Terra satellite collected ...

A hellacious two weeks on Jupiter's moon Io

2014-08-04

Three massive volcanic eruptions occurred on Jupiter's moon Io within a two-week period last August, leading astronomers to speculate that these presumed rare "outbursts," which can send material hundreds of miles above the surface, might be much more common than astronomers thought. "We typically expect one huge outburst every one or two years, and they're usually not this bright," said Imke de Pater, professor and chair of astronomy at the University of California, Berkeley, and lead author of one of two papers describing the eruptions. "Here we had three extremely ...

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

Weakness of leukemic stem cells discovered

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: